GLGuixing Li

Guixing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guixing Li has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Laboratory Identification of Pseudohypercalcemia Induced by Hyperglobulinemia in Multiple Myeloma: A Case Report

    by Anjiang Zhao, Fan Zhong, Yankui Liu, Guixing Li

    Background: Pseudohypercalcemia is easily misdiagnosed in clinical practice, potentially leading to unnecessary interventions. Multiple myeloma (MM) presenting with concurrent hypergammaglobulinemia represents a rare etiology of pseudohypercalcemia, and there are few reports of systematic laboratory validation of this pathological entity. Methods: We report a patient with MM who presented with markedly elevated serum total calcium on routine biochemical testing. The hypercalcemia persisted despite 1 month of calcitonin therapy administered at an external hospital. After admission, the clinical laboratory team performed a panel of confirmatory assays, including direct ionized calcium measurement, post‐dilution linearity evaluation, inductively coupled plasma mass spectrometry (ICP‐MS) verification, and polyethylene glycol (PEG) precipitation testing. Results and Conclusions: The results confirmed that the elevation in serum total calcium was attributed to enhanced calcium binding to circulating globulins, secondary to hypergammaglobulinemia, rather than analytical interference in the detection system. During clinical follow‐up, serum total calcium levels normalized progressively in parallel with the decline in globulin levels following targeted anti‐myeloma therapy. This case demonstrates that clinicians and laboratory professionals should maintain a high index of suspicion for pseudohypercalcemia when encountering patients with marked paraproteinemia or abnormal circulating macromolecules. A multimodal differential diagnostic approach using complementary laboratory indicators is warranted to avoid unnecessary examinations and interventions, thereby reducing the waste of medical resources and preventing potential adverse events associated with inappropriate treatment.

  • Open Access

    The Diagnostic Value of the Random Urine Potassium‒Creatinine Ratio to the Synchronous Serum Potassium Concentration Squared for Renal Potassium Loss in Hypokalemia Patients

    by Xinyi Wang, Fei Ding, Xinyi Huang, Yong He, Guixing Li

    Background: Few parameters are available for diagnosing renal potassium loss in emergency patients or patients receiving treatment. This study aimed to investigate the ratio of random urine potassium‒creatinine to the synchronous serum potassium concentration squared ([UK/UCr]/SK 2 ) and compare it with other parameters in the diagnostic ability of renal potassium loss. Methods: This single‐center study enrolled 380 subjects, including 218 hypokalemia patients (91 with nonrenal potassium loss and 127 with renal potassium loss) and 162 normal potassium controls. The values of serum and urine were based on laboratory data. Groups were compared in pairs, and the ROC curve analysis was used to evaluate the predictive ability of parameters related to renal potassium loss. Results: (UK/UCr)/SK 2 was significantly elevated in potassium loss patients, especially in females. Moreover, a greater (UK/UCr)/SK 2 ratio was observed in those with nonrenal potassium loss, which demonstrated a trend toward increases in the normal potassium, nonrenal potassium loss, and renal potassium loss groups among males and females. Ultimately, the AUC of (UK/UCr)/SK 2 was the highest at 0.880 (95% CI: 0.822–0.938) in males and 0.878 (95% CI: 0.831–0.924) in females for potassium loss diagnosis. Conclusion: Random (UK/UCr)/SK 2 has good diagnostic value for renal potassium loss in patients with hypokalemia. Given that these serum and random urine parameters are easily obtainable from patients during treatment, regularly observing (UK/UCr)/SK 2 may prove to be an effective indicator.

  • Open Access

    Risk factors for developing hungry bone syndrome after parathyroidectomy for secondary hyperparathyroidism

    by Mengting Yin, Xin Nie, Qianhui Liu, Yu Zhou, Lijing Yang, Siyu Chen, Ming Ma, Lan Bai, Yong He, Guixing Li

    Background Parathyroidectomy is recommended for patients with secondary hyperparathyroidism and has been proven to reduce all-cause mortality and cardiovascular mortality. Hungry bone syndrome is a common complication of parathyroidectomy. Therefore, identifying the preoperative risk factor for hungry bone syndrome is meaningful. In this study, we aimed to determine possible risk factors and their thresholds for hungry bone syndrome after parathyroidectomy for patients with secondary hyperparathyroidism. Methods Participants with secondary hyperparathyroidism who underwent parathyroidectomy were finally enrolled in this study. Hungry bone syndrome is defined as immediate postoperative hypocalcemia (calcium ≤ 2.1 mmol/L) and/or prolonged hypocalcemia (> 4 days) after parathyroidectomy. Clinical information and preoperative and postoperative laboratory data were collected. Results In all, 92 participants with secondary hyperparathyroidism who underwent parathyroidectomy were finally enrolled in this study. Among them, 61 patients (66.3%) experienced hungry bone syndrome after parathyroidectomy with a mean age of 44.3 years. Patients who experienced hungry bone syndrome had a higher preoperative parathyroid hormone value (263 (221, 329) vs. 139 (91, 187); P = 0.000) and phosphate value (2.42 ± 0.23 vs. 2.08 ± 0.61; P = 0.003) but a lower preoperative calcium level (2.41 ± 0.18 vs. 2.59 ± 0.20, P = 0.000). Meanwhile, patients with hungry bone syndrome were younger (44.3 years vs 51.9 years, P = 0.003). From the ROC curve, parathyroid hormone had the highest AUC = 0.868 (95% CI, 0.781–0.930) and sensitivity and specificity rates of 0.803 (0.682–0.894) and 0.903 (0.742–0.980), respectively, at a threshold of 215.9 pmol/L. Conclusions Secondary hyperparathyroidism patients with higher preoperative parathyroid hormone and phosphate levels and lower calcium levels were more likely to develop hungry bone syndrome.

  • 基础血清降钙素值对甲状腺髓样癌的鉴别诊断价值

    by Qian-Hui Liu, Xin Nie, Yong He, Meng-Ting Yin, Gui-Xing Li

    分析基础血清降钙素值(bCtn)在有甲状腺结节的高降钙素血症人群中对甲状腺髓样癌(MTC)的辅助诊断效能,以及术前血清bCtn、癌胚抗原(CEA)水平与MTC肿瘤分期的关系。 系统回顾四川大学华西医院2011–2020年收治的58名MTC和2016–2020年收治的84名非MTC患者的临床、病理、影像和检验资料,建立ROC曲线计算bCtn和CEA对MTC的诊断效能,比较不同肿瘤原发灶的情况和区域淋巴结受累情况的MTC患者术前bCtn、CEA水平差异。 bCtn从有甲状腺结节的高降钙素血症人群中诊断MTC的最佳截断值为31.54 pg/mL(男性)和22.60 pg/mL(女性)。不同T分期的MTC患者术前bCtn水平差异有统计学意义(H=16.166,P=0.001)、术前CEA水平差异有统计学意义(H=9.447,P=0.024)。不同N分期的MTC患者术前bCtn水平差异有统计学意义(H=7.919,P=0.019)、术前CEA水平差异有统计学意义(H=7.934,P=0.019)。 血清bCtn在有甲状腺结节的高降钙素血症人群中诊断MTC的最佳截断值分别为31.54 pg/mL(男性)和22.60 pg/mL(女性)。


  • Open Access

    Polyethylene Glycol Precipitation to Avoid Misdiagnosis of Insulin Autoimmune Syndrome: A Case Report and Testing Pathway in Medical Laboratories

    by Yuping Zeng, Guixing Li, Haolan Song

    Yuping Zeng, M.D., Guixing Li, Ph.D., and Haolan Song, M.D.. Ann Lab Med 2022;42:609-11. https://doi.org/10.3343/alm.2022.42.5.609


  • Open Access

    Fasting plasma lactate: A diagnosis and staging biomarker with superior performance in adult nonalcoholic fatty liver disease

    by Nie Xin, E Jianfei, He He, Ding Fei, Song Haolan, Liu Qianhui, Yin Mengting, He Yong, Li Guixing

    Purpose: For the assessment and staging of metabolic diseases such as obesity and type 2 diabetes mellitus (T2DM), fasting plasma lactate (FPL) has been a useful marker. However, it has never been used to evaluate nonalcoholic fatty liver disease (NAFLD). Since NAFLD is one of the significant metabolic syndromes, we investigated whether FPL can be used as a biomarker for diagnosing and staging NAFLD. Methods: A total of 102 patients who were diagnosed with NAFLD and 100 healthy control between October 2018 and September 2019 were enrolled in our study. We determined the levels of FPL, total cholesterol(TC), triglycerides (TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting plasma glucose (FPG), fasting insulin(FINS), and homeostasis model assessment of insulin resistance (HOMA-IR). We performedreceiver operating characteristic (ROC) analysis to evaluate their diagnostic performance. Results: In NAFLD patients, we found FPL, ALT, AST, TG, FPG, FINS, and HOMA-IR levels to be elevated while HDL-C level was reduced (P < 0.05). FPL, FPG, FINS, and HOMA-IR levels were higher in mild NAFLD patients than moderate to severe ones (P < 0.05). For NAFLD diagnosis and staging, the areas under the ROC curve (AUC) of FPL were 0.973 and 0.999, making it clearly (P < 0.05) superior to other biomarkers.For diagnosing and staging NAFLD, the cutoff value of1.285 mmol/L and 2.370 mmol/L for FPL had the highest validity, respectively. The sensitivity, specificity, negative likelihood ratio (LR-), and positive likelihood ratio (LR+) were 87.25%, 98.00%, 0.13, and 43.63 for the diagnosis cutoff value and. 92.19%, 97.37%, 0.08, and 35.05 for staging, respectively.In addition, for NAFLD patients, FPL positively correlated with TG, FPG, FINS, and HOMA-IR (P < 0.05).Conclusion: Thus, in adult NAFLD, FPL can be used as a diagnosis and staging biomarker with superior performance.


  • Open Access

    Corrigendum: Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China

    by Qianhui Liu, Mengting Yin, Guixing Li

    Corrigendum: Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China

  • Open Access

    Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China

    by Qianhui Liu, Mengting Yin, Guixing Li

    Objective: Antithyroglobulin antibody (TgAb) is a potential tumour marker for detecting differentiated thyroid cancer (DTC) recurrence, but insufficient data have supported its clinical applications. Our study aimed to describe the changing trend of TgAb after surgery and identify the relationship between this trend and clinical outcomes.Patients and Methods: We reviewed the electronic records of 1,686 DTC patients who had undergone total thyroidectomy (TT) and radioactive iodine (131I) therapy at West China Hospital of Sichuan University from January 2015 to December 2017. Finally, 289 preoperative TgAb-positive DTC patients were included and divided into four subgroups depending on the clinical outcome: Group A (tumour free), Group B (uncertain), Group C (incomplete biochemical response), and Group D (structural disease). The patient demographics, tumour characteristics, operations, pathology reports, and all serological biomarkers were reviewed and compared, and the prognostic efficacy of TgAb was evaluated.Results: Among all 1,686 patients, 393 (23.65%) were TgAb positive (>40 IU/ml) preoperatively. The TgAb level in Group A decreased significantly after surgery and 131I therapy and stabilised at a low level after 1–2 years of 131I therapy. However, in the other three groups, the decrease in TgAb was not significant after treatment. Conversely, TgAb declined slowly and remained stable or increased. The variations in TgAb relative to the preoperative level of Group A were significantly larger than those of Groups B, C, and D at most time points of follow-up (p < 0.001). By receiver operating characteristic (ROC) analyses, the variations of TgAb > −77.9% at 6 months after 131I therapy (area under the curve (AUC) = 0.862; p < 0.001) and TgAb > −88.6% at 2 years after 131I therapy (AUC = 0.901; p < 0.001) had good prognostic efficacy in tumour-free survival. When the variation in TgAb > −88.6% at 2 years after 131I therapy was incorporated as a variable in the American Thyroid Association (ATA) categories, both intermediate- and high-risk patients also had a significantly increased chance of being tumour free (from 75.68% to 93.88% and 42.0% to 82.61%, respectively).Conclusions: For preoperative TgAb-positive DTC patients, variations in TgAb > −77.9% at 6 months after 131I therapy and TgAb > −88.6% at 2 years after 131I therapy had good prognostic efficacy. Their incorporation as variables in the ATA risk stratification system could more accurately predict disease-free survival.


  • Open Access

    Diagnostic performance of the calcium/phosphate ratio for primary hyperparathyroidism in southwest China

    by Mengting Yin, Qianhui Liu, Qingzhong Wang, Yong He, Haolan Song, Xin Nie, Guixing Li

    Background: The diagnosis of primary hyperparathyroidism (PHPT) remains a challenge because of increased asymptomatic PHPT or patients with normocalcaemic PHPT (NPHPT). In addition, some primary hospitals in China have no equipment to measure parathyroid hormone (PTH) levels. Therefore, an additional, simple, and inexpensive laboratory biochemical marker is urgently needed. The calcium/phosphate (Ca/P) ratio and chloride/phosphate (Cl/P) ratio have been proposed as suitable tools to diagnose PHPT in Europe; however, the Ca/P ratio has never been tested in China. We aimed to conduct a confirmatory study to explore the diagnostic performance of the Ca/P ratio for PHPT in China. Methods: From January 2015 to December 2020, a total of 155 patients who underwent parathyroidectomy (143 PHPT patients and 12 NPHPT patients) and 153 controls were enrolled in this single-center , retrospective study. Serum calcium, phosphate, parathyroid hormone, 25-hydroxyvitamin vitamin D (25(OH) vitamin D), chloride, alanine transaminase (ALT), aspartate aminotransaminase (AST), estimated glomerular filtration rate (eGFR), and creatinine levels were recorded for all the study participants. Pairwise comparisons were made between groups, and the diagnostic performance of the Ca/P ratio was determined using receiver-operating characteristic (ROC) analysis. Results: Patients with PHPT had a higher Ca/P ratio than controls (P < 0.001). A Ca/P ratio above 2.94 with a sensitivity of 95.5% and specificity of 98.7% can distinguish PHPT patients from healthy individuals. This index was positively correlated with the PTH level (r = 0.875, P < 0.001). Conclusion: The Ca/P ratio is an ideal and inexpensive indicator for diagnosing PHPT in China when using a cut-off value of 2.94.


  • Open Access

    Updated Cutoff Values of Basal Serum Calcitonin to Discriminate True Medullary Thyroid Cancer from Other Conditions of Hypercalcitoninemia

    by Qianhui Liu, Xin Nie, Yong He, Guixing Li

    Background Calcitonin (Ctn) is a tumor marker of medullary thyroid carcinoma (MTC). However, serum Ctn cutoff values for MTC diagnosis are still under discussion. This study aimed to identify the cutoff values of Ctn and explore the relationship between two tumor markers (Ctn and carcinoembryonic antigen (CEA)) and disease burden. Methods This was a retrospective study conducted in West China Hospital of Sichuan University. We included 61 MTC patients and 235 non-MTC patients with nonspecific elevation of Ctn (> 9.52 pg/mL for males and > 6.40 pg/mL for females) and collected patients’ demographic information, essential serological indicators, cervical ultrasound and pathological reports. Results Unlike MTC, papillary thyroid carcinoma (40.85%), uremia (18.73%), chronic renal disease (10.21%) and inflammation (8.94%) commonly occurred with hypercalcitoninemia. The Ctn cutoff values were 38.24 pg/mL for males and 26.00 pg/mL for females. The Ctn level was found to be positively related to the largest tumor diameter (r = 0.702). Serum Ctn levels were significantly higher in patients with lymph node metastasis than in those without (P < 0.05), but CEA levels did not differ (P > 0.05). Conclusion The best Ctn cutoff values for Chinese people to discriminate MTC from other hypercalcitoninemia conditions are 38.24 pg/mL for males and 26.00 pg/mL for females.